Cargando…
Autologous peripheral blood-derived stem cells transplantation for treatment of no-option angiitis-induced critical limb ischemia: 10-year management experience
BACKGROUND: Previous studies have demonstrated that no-option angiitis-induced critical limb ischemia (NO-AICLI) could be significantly improved by transplantation of peripheral blood-derived stem cells (PBDSCs). Additionally, a randomized controlled trial (RCT) recently conducted by us suggested th...
Autores principales: | Fang, Gang, Jiang, Xiaolang, Fang, Yuan, Pan, Tianyue, Liu, Hao, Ren, Bichen, Wei, Zheng, Gu, Shiyang, Chen, Bin, Jiang, Junhao, Shi, Yun, Guo, Daqiao, Liu, Peng, Fu, Weiguo, Dong, Zhihui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594448/ https://www.ncbi.nlm.nih.gov/pubmed/33115517 http://dx.doi.org/10.1186/s13287-020-01981-4 |
Ejemplares similares
-
Autologous Stem Cells Transplantation for No-Option Angiitis-Induced Critical Limb Ischemia: Recurrence and New Lesion
por: Liu, Hao, et al.
Publicado: (2022) -
Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia
por: Jiang, Xiaolang, et al.
Publicado: (2021) -
A Five‐Year Study of the Efficacy of Purified CD34+ Cell Therapy for Angiitis‐Induced No‐Option Critical Limb Ischemia
por: Fang, Yuan, et al.
Publicado: (2018) -
Three‐year outcomes of peripheral blood mononuclear cells vs purified CD34
(+) cells in the treatment of angiitis‐induced no‐option critical limb ischemia and a cost‐effectiveness assessment: A randomized single‐blinded noninferiority trial
por: Liu, Hao, et al.
Publicado: (2021) -
The peripheral blood mononuclear cells versus purified CD34(+) cells transplantation in patients with angiitis-induced critical limb ischemia trial: 5-year outcomes and return to work analysis—a randomized single-blinded non-inferiority trial
por: Liu, Hao, et al.
Publicado: (2022)